Literature DB >> 23329013

Fat mass and obesity-associated gene enhances oxidative stress and lipogenesis in nonalcoholic fatty liver disease.

Jianjin Guo1, Wei Ren, Aimei Li, Ying Ding, Wanhua Guo, Dongming Su, Cheng Hu, Kuanfeng Xu, Heng Chen, Xinyu Xu, Tao Yang, Weiping Jia.   

Abstract

BACKGROUND AND AIM: Nonalcoholic fatty liver disease (NAFLD) is strongly associated with obesity, hyperlipidemia, and type 2 diabetes mellitus. Several studies have found that fat mass and the obesity-associated (FTO) gene is linked to obesity. The aim of this work is to investigate the expression and function of FTO in liver with lipid metabolism diseases.
METHODS: We investigated the basal FTO expression in an NAFLD rat model and compared it with control subjects. The function of FTO in lipid metabolism was further studied in L02 cells through overexpression experiments.
RESULTS: A significant increase in FTO mRNA and protein levels was found in the NAFLD group. In addition, the FTO levels were positively associated with malondialdehyde and superoxide dismutase concentrations. FTO overexpression in L02 cells enhanced lipogenesis and oxidative stress.
CONCLUSIONS: This study demonstrates that increased FTO levels in the liver are involved in oxidative stress and lipid deposition, which characterize NAFLD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23329013     DOI: 10.1007/s10620-012-2516-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Risk of all-cause and cardiovascular mortality in patients with chronic liver disease.

Authors:  Giovanni Targher; Giacomo Zoppini; Christopher P Day
Journal:  Gut       Date:  2010-12-15       Impact factor: 23.059

2.  The common rs9939609 gene variant of the fat mass- and obesity-associated gene FTO is related to fat cell lipolysis.

Authors:  Kerstin Wåhlén; Eva Sjölin; Johan Hoffstedt
Journal:  J Lipid Res       Date:  2007-11-29       Impact factor: 5.922

3.  Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning.

Authors:  L Zhu; S Fukuda; G Cordis; D K Das; N Maulik
Journal:  FEBS Lett       Date:  2001-11-23       Impact factor: 4.124

4.  Obesity-susceptibility loci have a limited influence on birth weight: a meta-analysis of up to 28,219 individuals.

Authors:  Tuomas O Kilpeläinen; Marcel den Hoed; Ken K Ong; Anders Grøntved; Soren Brage; Karen Jameson; Cyrus Cooper; Kay-Tee Khaw; Ulf Ekelund; Nicholas J Wareham; Ruth J F Loos
Journal:  Am J Clin Nutr       Date:  2011-01-19       Impact factor: 7.045

5.  Inactivation of the Fto gene protects from obesity.

Authors:  Julia Fischer; Linda Koch; Christian Emmerling; Jeanette Vierkotten; Thomas Peters; Jens C Brüning; Ulrich Rüther
Journal:  Nature       Date:  2009-02-22       Impact factor: 49.962

6.  NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study.

Authors:  Leon A Adams; Oliver R Waters; Matthew W Knuiman; Robert R Elliott; John K Olynyk
Journal:  Am J Gastroenterol       Date:  2009-03-17       Impact factor: 10.864

7.  Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors.

Authors:  Ben-Jian Zhang; Dan Xu; Yu Guo; Jie Ping; Liao-Bin Chen; Hui Wang
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-10-30       Impact factor: 2.557

8.  Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia.

Authors:  Holger Doege; Dirk Grimm; Alaric Falcon; Bernice Tsang; Theresa A Storm; Hui Xu; Angelica M Ortegon; Melissa Kazantzis; Mark A Kay; Andreas Stahl
Journal:  J Biol Chem       Date:  2008-06-03       Impact factor: 5.157

9.  A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity.

Authors:  Timothy M Frayling; Nicholas J Timpson; Michael N Weedon; Eleftheria Zeggini; Rachel M Freathy; Cecilia M Lindgren; John R B Perry; Katherine S Elliott; Hana Lango; Nigel W Rayner; Beverley Shields; Lorna W Harries; Jeffrey C Barrett; Sian Ellard; Christopher J Groves; Bridget Knight; Ann-Marie Patch; Andrew R Ness; Shah Ebrahim; Debbie A Lawlor; Susan M Ring; Yoav Ben-Shlomo; Marjo-Riitta Jarvelin; Ulla Sovio; Amanda J Bennett; David Melzer; Luigi Ferrucci; Ruth J F Loos; Inês Barroso; Nicholas J Wareham; Fredrik Karpe; Katharine R Owen; Lon R Cardon; Mark Walker; Graham A Hitman; Colin N A Palmer; Alex S F Doney; Andrew D Morris; George Davey Smith; Andrew T Hattersley; Mark I McCarthy
Journal:  Science       Date:  2007-04-12       Impact factor: 47.728

10.  Hypothalamic FTO is associated with the regulation of energy intake not feeding reward.

Authors:  Pawel K Olszewski; Robert Fredriksson; Agnieszka M Olszewska; Olga Stephansson; Johan Alsiö; Katarzyna J Radomska; Allen S Levine; Helgi B Schiöth
Journal:  BMC Neurosci       Date:  2009-10-27       Impact factor: 3.288

View more
  32 in total

1.  GR-mediated FTO transactivation induces lipid accumulation in hepatocytes via demethylation of m6A on lipogenic mRNAs.

Authors:  Yun Hu; Yue Feng; Luchu Zhang; Yimin Jia; Demin Cai; Shu-Bing Qian; Min Du; Ruqian Zhao
Journal:  RNA Biol       Date:  2020-03-09       Impact factor: 4.652

2.  FTO contributes to hepatic metabolism regulation through regulation of leptin action and STAT3 signalling in liver.

Authors:  Amélie Bravard; Guillaume Vial; Marie-Agnès Chauvin; Yves Rouillé; Bernard Bailleul; Hubert Vidal; Jennifer Rieusset
Journal:  Cell Commun Signal       Date:  2014-01-10       Impact factor: 5.712

3.  Impact of gentamicin coadministration along with high fructose feeding on progression of renal failure and metabolic syndrome in Sprague-Dawley rats.

Authors:  Zaid O Ibraheem; Rusliza Basir; Ahmad Kh Aljobory; Omar E Ibrahim; Ajwad Alsumaidaee; Mun Fee Yam
Journal:  Biomed Res Int       Date:  2014-06-23       Impact factor: 3.411

4.  FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.

Authors:  Daniel Pineda-Tenor; Juan Berenguer; María A Jiménez-Sousa; Mónica García-Alvarez; Teresa Aldámiz-Echevarria; Ana Carrero; Sonia Vázquez-Morón; Pilar García-Broncano; Cristina Diez; Francisco Tejerina; María Guzmán-Fulgencio; Salvador Resino
Journal:  BMC Med       Date:  2014-11-03       Impact factor: 8.775

5.  The Fto Gene Regulates the Proliferation and Differentiation of Pre-Adipocytes in Vitro.

Authors:  Yang Jiao; Jingying Zhang; Lunjie Lu; Jiaying Xu; Liqiang Qin
Journal:  Nutrients       Date:  2016-02-19       Impact factor: 5.717

6.  The Effects of Extra Virgin Olive Oil on Alanine Aminotransferase, Aspartate Aminotransferase, and Ultrasonographic Indices of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients Undergoing Low Calorie Diet.

Authors:  Farzad Shidfar; Samaneh Sadat Bahrololumi; Saeid Doaei; Assieh Mohammadzadeh; Maryam Gholamalizadeh; Ali Mohammadimanesh
Journal:  Can J Gastroenterol Hepatol       Date:  2018-04-17

7.  The (FTO) gene polymorphism is associated with metabolic syndrome risk in Egyptian females: a case- control study.

Authors:  Mina S Khella; Nadia M Hamdy; Ashraf I Amin; Hala O El-Mesallamy
Journal:  BMC Med Genet       Date:  2017-09-16       Impact factor: 2.103

8.  Relationship between fat mass and obesity-associated gene expression and type 2 diabetes mellitus severity.

Authors:  Qiuling Wang; Jinhuan Wang; Haixia Lin; Xuechen Huo; Qiaoling Zhu; Min Zhang
Journal:  Exp Ther Med       Date:  2018-01-15       Impact factor: 2.447

9.  Genetic Associations of Obesity: The Fat-Mass and Obesity-Associated (FTO) Gene.

Authors:  Adam C Ehrlich; Frank K Friedenberg
Journal:  Clin Transl Gastroenterol       Date:  2016-01-28       Impact factor: 4.488

Review 10.  Mechanisms of RNA N6-Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology.

Authors:  Jiahua Lu; Junjie Qian; Shengyong Yin; Lin Zhou; Shusen Zheng; Wu Zhang
Journal:  Front Oncol       Date:  2020-07-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.